查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1712540

全球生物可吸收植入物市场 - 2025-2033

Global Bioresorbable Implants Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球生物可吸收植入物市场规模达到 70 亿美元，预计到 2033 年将达到 143.4 亿美元，在 2025-2033 年预测期内的复合年增长率为 7.4%。

生物可吸收植入物是由特殊设计的聚合物製成的医疗器械，这些聚合物会随着时间的推移在体内自然溶解或降解，因此在完成功能后无需进行手术移除。这些植入物由疏水或亲水性聚合物组成，旨在支持各种医疗应用中的癒合过程，特别是手术后的癒合过程。

它们具有多种形式，常用于骨科手术、组织修復和药物传输系统。随着生物可吸收植入物逐渐分解为可被人体安全吸收或排泄的无毒副产品，它们提供了一种比永久性植入物侵入性更小、对患者更友好的替代方案，从而降低了长期併发症的风险和额外手术的需要。

市场动态：

驾驶员和约束装置

采用创新材料的先进植入物正在蓬勃发展

利用创新材料的植入物的不断发展极大地推动了生物可吸收植入物市场的成长。材料科学的进步导致了可生物吸收的聚合物和复合材料的产生，这些聚合物和复合材料具有更高的机械强度、生物相容性和可控制的降解率。例如，将生物活性玻璃和镁基合金融入植入物设计中，增强了其功能和癒合能力。

这些创新使得植入物的发展不仅能支持癒合，还能促进组织再生，进而扩大其在各个医学专业的应用。 2025年1月，可吸收骨科植入物的先驱Bioretec已完成其CE标誌审批流程，并可在欧盟和承认CE标誌市场授权的非欧洲国家开始商业化其RemeOs创伤螺丝产品组合。此项全面批准涵盖所有管状和非管状产品设计，尺寸范围从直径 2.0 毫米至 4.0 毫米，长度从 8 毫米至 50 毫米。核准的适应症包括使用这些螺丝钉对成人和儿童患者的上肢和下肢（手和前脚除外）进行骨折和错位固定。

此外，将感测器和药物传输系统等智慧技术融入生物可吸收植入物中，可实现即时监测和针对性治疗，进一步改善患者的治疗效果。这些技术进步使生物可吸收植入物更加有效和多功能，从而加速其在临床环境中的应用。

设计和製造成本高

设计和製造生物可吸收植入物的成本高昂仍然是市场更广泛采用的主要障碍。这些植入物需要先进的材料、专门的生产技术以及广泛的研究和测试，以确保生物相容性和精确的降解率。 3D 列印、聚合物共混和表面改质等製程需要精密的设备和熟练的劳动力，所有这些都大大增加了生产成本。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 依材料类型分类的片段
  • 按应用程式截取的程式码片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第三章：动态

  • 影响因素
    • 驱动程式
      • 批准数量不断增加
      • 创新材料植入物的发展日新月异
    • 限制
      • 设计和製造成本高
      • 医疗专业人员的认知度有限
    • 机会
      • 转向微创和以患者为中心的医疗保健解决方案
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第五章：生物可吸收植入物市场（依材料类型）

  • 金属
  • 聚合物
  • PLGA-聚乳酸-羟基乙酸共聚物
  • PLLA-聚L-乳酸
  • PGA-聚乙醇酸
  • PLA-聚乳酸
  • 其他的

第六章：生物可吸收植入物市场（依应用）

  • 心血管
  • 骨科
  • 其他的

第七章：生物可吸收植入物市场（依最终用户划分）

  • 医院
  • 门诊手术中心
  • 其他的

第八章：生物可吸收植入物市场，依区域市场分析与成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • Bioretec Ltd
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • Stryker Corporation
  • CONMED Corporation
  • Syntellix AG
  • Johnson & Johnson Medical Devices (DePuy Synthes)
  • Zimmer Biomet
  • NuVasive Inc.
  • KLS Martin Group
  • Smith+Nephew
  • Evonik Industries AG
  • indicates "similar data will be provided for each market player."

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MD887

The global bioresorbable implants market reached US$ 7.00 billion in 2024 and is expected to reach US$ 14.34 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.

Bioresorbable implants are medical devices made from specially engineered polymers that naturally dissolve or degrade within the body over time, eliminating the need for surgical removal once their function is complete. These implants are composed of either hydrophobic or hydrophilic polymers and are designed to support healing processes in various medical applications, particularly after surgery.

They are available in a wide range of forms and are commonly used in orthopedic procedures, tissue repair, and drug delivery systems. As they gradually break down into non-toxic byproducts that are safely absorbed or excreted by the body, bioresorbable implants offer a less invasive, patient-friendly alternative to permanent implants, reducing the risk of long-term complications and the need for additional surgeries.

Market Dynamics: Drivers & Restraints

Rising Development of Advanced Implants with Innovative Materials

The rising development of implants utilizing innovative materials is significantly driving the growth of the bioresorbable implants market. Advancements in material science have led to the creation of bioresorbable polymers and composites that offer improved mechanical strength, biocompatibility, and controlled degradation rates. For instance, the integration of bioactive glass and magnesium-based alloys into implant designs has enhanced their functionality and healing capabilities.

These innovations enable the development of implants that not only support healing but also promote tissue regeneration, thereby expanding their applications across various medical specialties. In January 2025, Bioretec, a pioneer in absorbable orthopedic implants, has completed its CE mark approval process and can start commercialization of its RemeOs Trauma Screw product portfolio within the European Union and non-European countries that recognize the CE mark market authorization. This comprehensive approval covers all cannulated and non-cannulated product designs, with sizes ranging from diameters of 2.0mm to 4.0mm and lengths from 8mm to 50mm. Indications approved include the use of these screws for fracture and malalignment fixations in both upper and lower extremities of adult and pediatric patients, excluding the hand and forefoot.

Additionally, the incorporation of smart technologies, such as sensors and drug delivery systems, into bioresorbable implants allows for real-time monitoring and targeted treatment, further enhancing patient outcomes. These technological advancements are making bioresorbable implants more effective and versatile, thereby accelerating their adoption in clinical settings.

High Cost of Designing and Manufacturing

The high cost of designing and manufacturing bioresorbable implants remains a major barrier to the market's broader adoption. These implants require advanced materials, specialized production techniques, and extensive research and testing to ensure biocompatibility and precise degradation rates. Processes like 3D printing, polymer blending, and surface modification demand sophisticated equipment and skilled labor, all of which significantly drive up production costs.

Segment Analysis

The global bioresorbable implants market is segmented based on material type, application, and end-user region.

Material Type:

PLGA (Poly lactic-co-glycolic acid) in the material type segment is expected to dominate the bioresorbable implants market.

PLGA (Poly lactic-co-glycolic acid) is expected to dominate the bioresorbable implants market due to its exceptional versatility, safety profile, and broad range of clinical applications. As a copolymer of lactic acid and glycolic acid, PLGA offers customizable degradation rates by simply altering the ratio of its two components, allowing it to be tailored for everything from short-term tissue scaffolds to longer-term orthopedic or cardiovascular support. Its biocompatibility and non-toxic degradation byproducts (carbon dioxide and water) make it ideal for implantation, with minimal risk of inflammation or rejection.

PLGA is already widely used in FDA-approved medical devices, including sutures, screws, pins, and drug-delivery systems, which has established a strong regulatory precedent for new product approvals. Moreover, PLGA's role in controlled drug release has expanded its utility beyond just structural support. Given its proven track record, ease of processing, and adaptability across various specialties like orthopedics, cardiology, and regenerative medicine, the PLGA segment is well-positioned to remain a leading force in the global bioresorbable implants market.

Geographical Analysis

North America is expected to dominate the global bioresorbable implants market.

North America is expected to dominate the bioresorbable implants market due to rising surgical volumes, growing adoption of advanced medical technologies, and increasing demand for patient-friendly treatment options. The region, particularly the United States, has seen a steady rise in procedures such as orthopedic repairs, soft tissue reconstruction, and cardiovascular interventions.

For instance, according to the American College of Rheumatology, in 2024, about 790,000 total knee replacements and 544,000 hip replacements were done every year in the U.S. This number continues to grow as our population ages. This increase in the number of procedures is expected to increase the demand for bioresorbable implants, as a large number of individuals in the region are hesitating about the removal surgery of implants.

Additionally, a strong focus on reducing long-term complications and avoiding secondary surgeries has led to higher acceptance of bioresorbable devices like screws, pins, and plates. Recent product approvals, such as magnesium-based bioresorbable implants, and growing use of materials like PLGA and PLLA further support this trend.

With a well-established regulatory pathway and a high level of awareness among healthcare providers, North America is expected to maintain its leading position in the global bioresorbable implants market. For instance, In March 2023, Bioretec Ltd received the market authorization of the U.S. Food and Drug Administration (FDA) for its pioneering RemeOs trauma screw to be used for healing of bone fractures aligned with the clinical trial.

Competitive Landscape

The global market players in the bioresorbable implants market include Bioretec Ltd, Stryker Corporation, CONMED Corporation, Syntellix AG, Johnson & Johnson Medical Devices (DePuy Synthes), Zimmer Biomet, NuVasive Inc., KLS Martin Group, Smith+Nephew, Evonik Industries AG, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global bioresorbable implants market report will provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Material Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Number of Approvals
      • 3.1.1.2. Rising Development of Implants with Innovative Materials
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Designing and Manufacturing
      • 3.1.2.2. Limited Awareness Among Healthcare Professionals
    • 3.1.3. Opportunity
      • 3.1.3.1. Shift Toward Minimally Invasive and Patient-centric Healthcare Solutions
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Bioresorbable Implants Market, By Material Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 5.1.2. Market Attractiveness Index, By Material Type
  • 5.2. Metallic*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Polymers
  • 5.4. PLGA- Poly lactic-co-glycolic acid
  • 5.5. PLLA- Poly L-lactide
  • 5.6. PGA- Polyglycolic Acid
  • 5.7. PLA- Polylactic Acid
  • 5.8. Others

6. Bioresorbable Implants Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Cardiovascular*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Orthopedics
  • 6.4. Others

7. Bioresorbable Implants Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Others

8. Bioresorbable Implants Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Bioretec Ltd*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Stryker Corporation
  • 10.3. CONMED Corporation
  • 10.4. Syntellix AG
  • 10.5. Johnson & Johnson Medical Devices (DePuy Synthes)
  • 10.6. Zimmer Biomet
  • 10.7. NuVasive Inc.
  • 10.8. KLS Martin Group
  • 10.9. Smith+Nephew
  • 10.10. Evonik Industries AG
  • indicates "similar data will be provided for each market player."

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us